# A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

> **NCT00888693** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 81 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ABT-288
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00888693
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888693, "A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00888693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*